(AXGN) Axogen - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05463X1063
AXGN: Grafts, Connectors, Protectors, Caps, Tools, Implants
Axogen Inc. stands at the forefront of peripheral nerve regeneration, offering a comprehensive suite of innovative solutions designed to transform traditional repair methods. Their flagship product, Avance Nerve Graft, is a revolutionary off-the-shelf allograft that eliminates the need for a second surgery, thereby reducing patient recovery time and complications. Complementing this are the AxoGuard products, which utilize porcine submucosa extracellular matrix (ECM) to create biological scaffolds that promote tissue repair without immune rejection risks. These include AxoGuard Nerve Connector for tensionless repairs, Nerve Protector for wrapping and reinforcing damaged nerves, HA+ Nerve Protector with a hyaluronate-alginate gel coating for enhanced protection, and Nerve Cap to prevent neuroma formation. Additionally, AxoTouch aids in assessing nerve regeneration through skin innervation measurement. Targeting a niche yet critical market, Axogens products are sought by reconstructive surgeons, orthopedic specialists, and oral surgeons, underscoring their role in advancing patient care.
Looking ahead, Axogens future prospects are intriguing. With a market cap of $792.15M, the companys high P/B ratio of 7.96 reflects market confidence in its asset value and growth potential. Despite a negative RoE, indicative of strategic investments in innovation and market expansion, the forward P/E of 50 signals anticipation of substantial growth. As the demand for effective nerve repair solutions rises, Axogens valuation may be justified by its ability to maintain its leadership position and expand its product portfolio. The companys focus on research and development, coupled with its strong market position, positions it as a compelling player in the medical technology sector, poised for continued growth and innovation.
Additional Sources for AXGN Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AXGN Stock Overview
Market Cap in USD | 786m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1990-03-27 |
AXGN Stock Ratings
Growth 5y | 34.1% |
Fundamental | 9.34% |
Dividend | 0.30% |
Rel. Strength Industry | 114 |
Analysts | 4.67/5 |
Fair Price Momentum | 17.99 USD |
Fair Price DCF | 0.67 USD |
AXGN Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 1.0% |
AXGN Growth Ratios
Growth Correlation 3m | 57.6% |
Growth Correlation 12m | 92.7% |
Growth Correlation 5y | -29.9% |
CAGR 5y | 14.78% |
CAGR/Max DD 5y | 0.17 |
Sharpe Ratio 12m | 0.55 |
Alpha | 107.41 |
Beta | 0.39 |
Volatility | 53.78% |
Current Volume | 377.7k |
Average Volume 20d | 601.9k |
As of March 14, 2025, the stock is trading at USD 17.16 with a total of 377,729 shares traded.
Over the past week, the price has changed by -3.43%, over one month by -5.40%, over three months by +21.19% and over the past year by +113.17%.
Neither. Based on ValueRay Fundamental Analyses, Axogen is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 9.34 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AXGN as of March 2025 is 17.99. This means that AXGN is currently overvalued and has a potential downside of 4.84%.
Axogen has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy AXGN.
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AXGN Axogen will be worth about 19.7 in March 2026. The stock is currently trading at 17.16. This means that the stock has a potential upside of +14.57%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 25 | 45.7% |
Analysts Target Price | 18.5 | 7.8% |
ValueRay Target Price | 19.7 | 14.6% |